Point of Care lipid Test Market By Product Type (Devices, Consumables), By Application (Endogenous Hyperlipemia, Combined hyperlipidemia, Familial Hypercholesterolemia, Others), By End User (Hospitals and Clinics, Diagnostic Laboratories, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global point of care lipid test market accounted for $284.86 million in 2021 and is expected to reach $426.58 million by 2031, registering a CAGR of 4.1% from 2022 to 2031.
Point of care (POC) test is one of the medical tests that assist in identifying chronic complications inside the human body. This means that, in contrast to other traditional diagnostic procedures, point-of-care testing assists in quickly diagnosing issues and shorten hospital stays. The point-of-care diagnostics assists in delivering real-time results in a matter of minutes. Point of care (POC) lipid test is performed to determine how well the lipids in the cells are working. When cholesterol levels rise, it changes how lipids work in the body and, as a result, can cause serious ailments such as heart attacks and coronary artery disease.
It is estimated that point of care lipid test market is expected to experience significant market growth during the forecast period owing to the rise in awareness on medical therapeutics on a global scale. In addition, increase in number of patients suffering from cardiovascular diseases, obesity, and other diseases further propel the growth of the market. However, rising cost associated with R&D of point of care lipid test is expected to impede the market growth. . In contrast, big investments in healthcare sector infrastructure and need for advancement in technology are anticipated to provide significant growth opportunities for the point of care lipid test market.
The Point of care lipid test market is segmented on the basis of product type, application, end user, and region. Depending on product, the market is classified into devices and consumables. On the basis of application, the market is divided into endogenous hyperlipidemia, combined hyperlipidemia , familial hypercholesterolemia, and others. By end user, the market is classified into hospitals & Clinics, diagnostics laboratories , and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global point of care lipid test market. The key companies profiled in the report include Abbott Laboratories, Callegari, F. Hoffmann-La Roche Ltd., Menarini Group, Mico Bio Med, Nova Biomedical Corporation, SD biosensor, inc., Sinocare Inc., VivaChek Biotech (Hangzhou) Co.,Ltd, and Zoetis Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the point of care lipid test market analysis from 2021 to 2031 to identify the prevailing point of care lipid test market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the point of care lipid test market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global point of care lipid test market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product Type
Devices
Consumables
By Application
Endogenous Hyperlipemia
Combined hyperlipidemia
Familial Hypercholesterolemia
Others
By End User
Hospitals and Clinics
Diagnostic Laboratories
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Abbott Laboratories
Callegari
F. Hoffmann-La Roche Ltd.
Menarini Group
Mico Bio Med
Nova Biomedical Corporation
SD Biosensor, Inc.
Sinocare Inc.
VivaChek Biotech (Hangzhou) Co.,Ltd
Zoetis Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Market dynamics
- 3.4.1.Drivers
- 3.4.1.1. Surge in obesity in populace
- 3.4.1.2. Increase in government initiatives to promote healthy lifestyle
- 3.4.1.3. Increase in prevalence of cardiovascular disease and diabetes
- 3.4.2.Restraints
- 3.4.2.1. High cost of product development
- 3.4.3.Opportunities
- 3.4.3.1. Growth potential of emerging economies
- 3.5.COVID-19 Impact Analysis on the market
- CHAPTER 4: POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2. Devices
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3. Consumables
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
- CHAPTER 5: POINT OF CARE LIPID TEST MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2. Endogenous Hyperlipemia
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3. Combined hyperlipidemia
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
- 5.4. Familial Hypercholesterolemia
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country
- 5.5. Others
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market share analysis by country
- CHAPTER 6: POINT OF CARE LIPID TEST MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2. Hospitals and Clinics
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
- 6.3. Diagnostic Laboratories
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
- 6.4. Others
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country
- CHAPTER 7: POINT OF CARE LIPID TEST MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Product Type
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Key market trends, growth factors and opportunities
- 7.2.5.1.2 Market size and forecast, by Product Type
- 7.2.5.1.3 Market size and forecast, by Application
- 7.2.5.1.4 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Key market trends, growth factors and opportunities
- 7.2.5.2.2 Market size and forecast, by Product Type
- 7.2.5.2.3 Market size and forecast, by Application
- 7.2.5.2.4 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Key market trends, growth factors and opportunities
- 7.2.5.3.2 Market size and forecast, by Product Type
- 7.2.5.3.3 Market size and forecast, by Application
- 7.2.5.3.4 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Product Type
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Key market trends, growth factors and opportunities
- 7.3.5.1.2 Market size and forecast, by Product Type
- 7.3.5.1.3 Market size and forecast, by Application
- 7.3.5.1.4 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Key market trends, growth factors and opportunities
- 7.3.5.2.2 Market size and forecast, by Product Type
- 7.3.5.2.3 Market size and forecast, by Application
- 7.3.5.2.4 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Key market trends, growth factors and opportunities
- 7.3.5.3.2 Market size and forecast, by Product Type
- 7.3.5.3.3 Market size and forecast, by Application
- 7.3.5.3.4 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Key market trends, growth factors and opportunities
- 7.3.5.4.2 Market size and forecast, by Product Type
- 7.3.5.4.3 Market size and forecast, by Application
- 7.3.5.4.4 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Key market trends, growth factors and opportunities
- 7.3.5.5.2 Market size and forecast, by Product Type
- 7.3.5.5.3 Market size and forecast, by Application
- 7.3.5.5.4 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Key market trends, growth factors and opportunities
- 7.3.5.6.2 Market size and forecast, by Product Type
- 7.3.5.6.3 Market size and forecast, by Application
- 7.3.5.6.4 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Product Type
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Key market trends, growth factors and opportunities
- 7.4.5.1.2 Market size and forecast, by Product Type
- 7.4.5.1.3 Market size and forecast, by Application
- 7.4.5.1.4 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Key market trends, growth factors and opportunities
- 7.4.5.2.2 Market size and forecast, by Product Type
- 7.4.5.2.3 Market size and forecast, by Application
- 7.4.5.2.4 Market size and forecast, by End User
- 7.4.5.3 India
- 7.4.5.3.1 Key market trends, growth factors and opportunities
- 7.4.5.3.2 Market size and forecast, by Product Type
- 7.4.5.3.3 Market size and forecast, by Application
- 7.4.5.3.4 Market size and forecast, by End User
- 7.4.5.4 Australia
- 7.4.5.4.1 Key market trends, growth factors and opportunities
- 7.4.5.4.2 Market size and forecast, by Product Type
- 7.4.5.4.3 Market size and forecast, by Application
- 7.4.5.4.4 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Key market trends, growth factors and opportunities
- 7.4.5.5.2 Market size and forecast, by Product Type
- 7.4.5.5.3 Market size and forecast, by Application
- 7.4.5.5.4 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Key market trends, growth factors and opportunities
- 7.4.5.6.2 Market size and forecast, by Product Type
- 7.4.5.6.3 Market size and forecast, by Application
- 7.4.5.6.4 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Product Type
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Key market trends, growth factors and opportunities
- 7.5.5.1.2 Market size and forecast, by Product Type
- 7.5.5.1.3 Market size and forecast, by Application
- 7.5.5.1.4 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Key market trends, growth factors and opportunities
- 7.5.5.2.2 Market size and forecast, by Product Type
- 7.5.5.2.3 Market size and forecast, by Application
- 7.5.5.2.4 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Key market trends, growth factors and opportunities
- 7.5.5.3.2 Market size and forecast, by Product Type
- 7.5.5.3.3 Market size and forecast, by Application
- 7.5.5.3.4 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Key market trends, growth factors and opportunities
- 7.5.5.4.2 Market size and forecast, by Product Type
- 7.5.5.4.3 Market size and forecast, by Application
- 7.5.5.4.4 Market size and forecast, by End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2021
- CHAPTER 9: COMPANY PROFILES
- 9.1 Abbott Laboratories
- 9.1.1 Company overview
- 9.1.2 Key Executives
- 9.1.3 Company snapshot
- 9.1.4 Operating business segments
- 9.1.5 Product portfolio
- 9.1.6 Business performance
- 9.1.7 Key strategic moves and developments
- 9.2 Callegari
- 9.2.1 Company overview
- 9.2.2 Key Executives
- 9.2.3 Company snapshot
- 9.2.4 Operating business segments
- 9.2.5 Product portfolio
- 9.2.6 Business performance
- 9.2.7 Key strategic moves and developments
- 9.3 F. Hoffmann-La Roche Ltd.
- 9.3.1 Company overview
- 9.3.2 Key Executives
- 9.3.3 Company snapshot
- 9.3.4 Operating business segments
- 9.3.5 Product portfolio
- 9.3.6 Business performance
- 9.3.7 Key strategic moves and developments
- 9.4 Menarini Group
- 9.4.1 Company overview
- 9.4.2 Key Executives
- 9.4.3 Company snapshot
- 9.4.4 Operating business segments
- 9.4.5 Product portfolio
- 9.4.6 Business performance
- 9.4.7 Key strategic moves and developments
- 9.5 Mico Bio Med
- 9.5.1 Company overview
- 9.5.2 Key Executives
- 9.5.3 Company snapshot
- 9.5.4 Operating business segments
- 9.5.5 Product portfolio
- 9.5.6 Business performance
- 9.5.7 Key strategic moves and developments
- 9.6 Nova Biomedical Corporation
- 9.6.1 Company overview
- 9.6.2 Key Executives
- 9.6.3 Company snapshot
- 9.6.4 Operating business segments
- 9.6.5 Product portfolio
- 9.6.6 Business performance
- 9.6.7 Key strategic moves and developments
- 9.7 SD Biosensor, Inc.
- 9.7.1 Company overview
- 9.7.2 Key Executives
- 9.7.3 Company snapshot
- 9.7.4 Operating business segments
- 9.7.5 Product portfolio
- 9.7.6 Business performance
- 9.7.7 Key strategic moves and developments
- 9.8 Sinocare Inc.
- 9.8.1 Company overview
- 9.8.2 Key Executives
- 9.8.3 Company snapshot
- 9.8.4 Operating business segments
- 9.8.5 Product portfolio
- 9.8.6 Business performance
- 9.8.7 Key strategic moves and developments
- 9.9 VivaChek Biotech (Hangzhou) Co.,Ltd
- 9.9.1 Company overview
- 9.9.2 Key Executives
- 9.9.3 Company snapshot
- 9.9.4 Operating business segments
- 9.9.5 Product portfolio
- 9.9.6 Business performance
- 9.9.7 Key strategic moves and developments
- 9.10 Zoetis Inc.
- 9.10.1 Company overview
- 9.10.2 Key Executives
- 9.10.3 Company snapshot
- 9.10.4 Operating business segments
- 9.10.5 Product portfolio
- 9.10.6 Business performance
- 9.10.7 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 2. POINT OF CARE LIPID TEST MARKET FOR DEVICES, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 3. POINT OF CARE LIPID TEST MARKET FOR CONSUMABLES, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 4. GLOBAL POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 5. POINT OF CARE LIPID TEST MARKET FOR ENDOGENOUS HYPERLIPEMIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 6. POINT OF CARE LIPID TEST MARKET FOR COMBINED HYPERLIPIDEMIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 7. POINT OF CARE LIPID TEST MARKET FOR FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 8. POINT OF CARE LIPID TEST MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 9. GLOBAL POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 10. POINT OF CARE LIPID TEST MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 11. POINT OF CARE LIPID TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 12. POINT OF CARE LIPID TEST MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 13. POINT OF CARE LIPID TEST MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 14. NORTH AMERICA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 15. NORTH AMERICA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 16. NORTH AMERICA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 17. NORTH AMERICA POINT OF CARE LIPID TEST MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 18. U.S. POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 19. U.S. POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 20. U.S. POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 21. CANADA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 22. CANADA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 23. CANADA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 24. MEXICO POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 25. MEXICO POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 26. MEXICO POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 27. EUROPE POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 28. EUROPE POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 29. EUROPE POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 30. EUROPE POINT OF CARE LIPID TEST MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 31. GERMANY POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 32. GERMANY POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 33. GERMANY POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 34. FRANCE POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 35. FRANCE POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 36. FRANCE POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 37. UK POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 38. UK POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 39. UK POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 40. ITALY POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 41. ITALY POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 42. ITALY POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 43. SPAIN POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 44. SPAIN POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 45. SPAIN POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 46. REST OF EUROPE POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 47. REST OF EUROPE POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 48. REST OF EUROPE POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 49. ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 50. ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 51. ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 52. ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 53. JAPAN POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 54. JAPAN POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 55. JAPAN POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 56. CHINA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 57. CHINA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 58. CHINA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 59. INDIA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 60. INDIA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 61. INDIA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 62. AUSTRALIA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 63. AUSTRALIA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 64. AUSTRALIA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 65. SOUTH KOREA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 66. SOUTH KOREA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 67. SOUTH KOREA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 68. REST OF ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 69. REST OF ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 70. REST OF ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 71. LAMEA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 72. LAMEA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 73. LAMEA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 74. LAMEA POINT OF CARE LIPID TEST MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 75. BRAZIL POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 76. BRAZIL POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 77. BRAZIL POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 78. SAUDI ARABIA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 79. SAUDI ARABIA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 80. SAUDI ARABIA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 81. SOUTH AFRICA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 82. SOUTH AFRICA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 83. SOUTH AFRICA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 84. REST OF LAMEA POINT OF CARE LIPID TEST MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 85. REST OF LAMEA POINT OF CARE LIPID TEST MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 86. REST OF LAMEA POINT OF CARE LIPID TEST MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 87. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 88. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 89. ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 90. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 91. ABBOTT LABORATORIES: NET SALES
- TABLE 92. ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 93. CALLEGARI: KEY EXECUTIVES
- TABLE 94. CALLEGARI: COMPANY SNAPSHOT
- TABLE 95. CALLEGARI: OPERATING SEGMENTS
- TABLE 96. CALLEGARI: PRODUCT PORTFOLIO
- TABLE 97. CALLEGARI: NET SALES
- TABLE 98. CALLEGARI: KEY STRATERGIES
- TABLE 99. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 100. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 101. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
- TABLE 102. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 103. F. HOFFMANN-LA ROCHE LTD.: NET SALES
- TABLE 104. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
- TABLE 105. MENARINI GROUP: KEY EXECUTIVES
- TABLE 106. MENARINI GROUP: COMPANY SNAPSHOT
- TABLE 107. MENARINI GROUP: OPERATING SEGMENTS
- TABLE 108. MENARINI GROUP: PRODUCT PORTFOLIO
- TABLE 109. MENARINI GROUP: NET SALES
- TABLE 110. MENARINI GROUP: KEY STRATERGIES
- TABLE 111. MICO BIO MED: KEY EXECUTIVES
- TABLE 112. MICO BIO MED: COMPANY SNAPSHOT
- TABLE 113. MICO BIO MED: OPERATING SEGMENTS
- TABLE 114. MICO BIO MED: PRODUCT PORTFOLIO
- TABLE 115. MICO BIO MED: NET SALES
- TABLE 116. MICO BIO MED: KEY STRATERGIES
- TABLE 117. NOVA BIOMEDICAL CORPORATION: KEY EXECUTIVES
- TABLE 118. NOVA BIOMEDICAL CORPORATION: COMPANY SNAPSHOT
- TABLE 119. NOVA BIOMEDICAL CORPORATION: OPERATING SEGMENTS
- TABLE 120. NOVA BIOMEDICAL CORPORATION: PRODUCT PORTFOLIO
- TABLE 121. NOVA BIOMEDICAL CORPORATION: NET SALES
- TABLE 122. NOVA BIOMEDICAL CORPORATION: KEY STRATERGIES
- TABLE 123. SD BIOSENSOR, INC.: KEY EXECUTIVES
- TABLE 124. SD BIOSENSOR, INC.: COMPANY SNAPSHOT
- TABLE 125. SD BIOSENSOR, INC.: OPERATING SEGMENTS
- TABLE 126. SD BIOSENSOR, INC.: PRODUCT PORTFOLIO
- TABLE 127. SD BIOSENSOR, INC.: NET SALES
- TABLE 128. SD BIOSENSOR, INC.: KEY STRATERGIES
- TABLE 129. SINOCARE INC.: KEY EXECUTIVES
- TABLE 130. SINOCARE INC.: COMPANY SNAPSHOT
- TABLE 131. SINOCARE INC.: OPERATING SEGMENTS
- TABLE 132. SINOCARE INC.: PRODUCT PORTFOLIO
- TABLE 133. SINOCARE INC.: NET SALES
- TABLE 134. SINOCARE INC.: KEY STRATERGIES
- TABLE 135. VIVACHEK BIOTECH (HANGZHOU) CO.,LTD : KEY EXECUTIVES
- TABLE 136. VIVACHEK BIOTECH (HANGZHOU) CO.,LTD : COMPANY SNAPSHOT
- TABLE 137. VIVACHEK BIOTECH (HANGZHOU) CO.,LTD : OPERATING SEGMENTS
- TABLE 138. VIVACHEK BIOTECH (HANGZHOU) CO.,LTD : PRODUCT PORTFOLIO
- TABLE 139. VIVACHEK BIOTECH (HANGZHOU) CO.,LTD : NET SALES
- TABLE 140. VIVACHEK BIOTECH (HANGZHOU) CO.,LTD : KEY STRATERGIES
- TABLE 141. ZOETIS INC.: KEY EXECUTIVES
- TABLE 142. ZOETIS INC.: COMPANY SNAPSHOT
- TABLE 143. ZOETIS INC.: OPERATING SEGMENTS
- TABLE 144. ZOETIS INC.: PRODUCT PORTFOLIO
- TABLE 145. ZOETIS INC.: NET SALES
- TABLE 146. ZOETIS INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1. SEGMENTATION OF POINT OF CARE LIPID TEST MARKET,2021-2031
- FIGURE 2. POINT OF CARE LIPID TEST MARKET,2021-2031
- FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 4. PORTER FIVE-1
- FIGURE 5. PORTER FIVE-2
- FIGURE 6. PORTER FIVE-3
- FIGURE 7. PORTER FIVE-4
- FIGURE 8. PORTER FIVE-5
- FIGURE 9. POINT OF CARE LIPID TEST MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 10. POINT OF CARE LIPID TEST MARKET,BY PRODUCT TYPE,2021(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DEVICES POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CONSUMABLES POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 13. POINT OF CARE LIPID TEST MARKET,BY APPLICATION,2021(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ENDOGENOUS HYPERLIPEMIA POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMBINED HYPERLIPIDEMIA POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF FAMILIAL HYPERCHOLESTEROLEMIA POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OTHERS POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 18. POINT OF CARE LIPID TEST MARKET,BY END USER,2021(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND CLINICS POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC LABORATORIES POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OTHERS POINT OF CARE LIPID TEST MARKET, 2021 AND 2031(%)
- FIGURE 22. POINT OF CARE LIPID TEST MARKET BY REGION,2021
- FIGURE 23. U.S. POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 24. CANADA POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 25. MEXICO POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 26. GERMANY POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 27. FRANCE POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 28. UK POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 29. ITALY POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 30. SPAIN POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 31. REST OF EUROPE POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 32. JAPAN POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 33. CHINA POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 34. INDIA POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 35. AUSTRALIA POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 36. SOUTH KOREA POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 37. REST OF ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 38. BRAZIL POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 39. SAUDI ARABIA POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 40. SOUTH AFRICA POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 41. REST OF LAMEA POINT OF CARE LIPID TEST MARKET,2021-2031($MILLION)
- FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 46. COMPETITIVE DASHBOARD
- FIGURE 47. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 48. TOP PLAYER POSITIONING, 2021
- FIGURE 49. ABBOTT LABORATORIES.: NET SALES ($MILLION)
- FIGURE 50. CALLEGARI.: NET SALES ($MILLION)
- FIGURE 51. F. HOFFMANN-LA ROCHE LTD..: NET SALES ($MILLION)
- FIGURE 52. MENARINI GROUP.: NET SALES ($MILLION)
- FIGURE 53. MICO BIO MED.: NET SALES ($MILLION)
- FIGURE 54. NOVA BIOMEDICAL CORPORATION.: NET SALES ($MILLION)
- FIGURE 55. SD BIOSENSOR, INC..: NET SALES ($MILLION)
- FIGURE 56. SINOCARE INC..: NET SALES ($MILLION)
- FIGURE 57. VIVACHEK BIOTECH (HANGZHOU) CO.,LTD .: NET SALES ($MILLION)
- FIGURE 58. ZOETIS INC..: NET SALES ($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook